Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-15, Stock:NVS, The news for the past five days is as follows:
2018-03-08: NEWS1: Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss.NEWS2: Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss.NEWS3: Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss.NEWS4: Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug.NEWS5: Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug.NEWS6: The Swiss Stock Market Climbed As Trade Concerns Ease.NEWS7: The Swiss Stock Market Climbed As Trade Concerns Ease.NEWS8: [$$] Syriza is undermining democracy in Greece.
2018-03-09: NEWS1: How AstraZeneca’s Revenues Trended in 4Q17.NEWS2: The Swiss Stock Market Finished Higher After U.S. Jobs Report.NEWS3: The Swiss Stock Market Finished Higher After U.S. Jobs Report.
2018-03-12: NEWS1: How AstraZeneca’s Respiratory Products Performed in 4Q17.NEWS2: The Swiss Stock Market Is Approaching The 9,000 Point Level.NEWS3: The Swiss Stock Market Is Approaching The 9,000 Point Level.NEWS4: How AstraZeneca’s Business Segments Performed in 4Q17.NEWS5: Novartis CEO Narasimhan remakes drugmaker's leadership as Wyss exits.NEWS6: Novartis says operations head Wyss resigning, names three to executive panel.
2018-03-13: NEWS1: How Novartis’s Revenues Trended in 4Q17.NEWS2: What’s Novartis’s Valuation in March 2018?.NEWS3: How AstraZeneca’s Other Products Portfolio Performed in 4Q17.NEWS4: The Swiss Stock Market Dropped Following Afternoon Sell-Off.NEWS5: The Swiss Stock Market Dropped Following Afternoon Sell-Off.
2018-03-14: NEWS1: Why Intellia Therapeutics Is Plunging Today.NEWS2: Why Intellia Therapeutics Is Plunging Today.NEWS3: Why Intellia Therapeutics Is Plunging Today.NEWS4: How Novartis’s Sandoz Performed in 4Q17.NEWS5: Cancer Space Takes Giant Strides: Are Patients Benefiting?.NEWS6: Cancer Space Takes Giant Strides: Are Patients Benefiting?.NEWS7: The Swiss Stock Market Dipped On Disappointing U.S. Data.NEWS8: The Swiss Stock Market Dipped On Disappointing U.S. Data.NEWS9: Novartis’s Innovative Medicines Business in 4Q17.NEWS10: What Analysts Recommend for AstraZeneca in March 2018.NEWS11: Cancer Space Takes Giant Strides: Are Patients Benefiting?.NEWS12: How Novartis’s Business Segments Performed in 4Q17.NEWS13: What Analysts Expect for AstraZeneca Going Forward.

Answer: Decrease